TRANSGENOMIC INC COM USD0.01(POST REV SPLIT) (TBIO)

0.21
0.05 19.23
OTC
Prev Close 0.26
Open 0.26
Day Low/High 0.17 / 0.26
52 Wk Low/High 0.26 / 0.70
Volume 514.91K
Exchange OTC
Shares Outstanding 26.86B
Market Cap 7.79M
Div & Yield N.A. (N.A)

Latest News

Transgenomic Closes Bridge Financing

Transgenomic, Inc. (OTCQB:TBIO) today reported that it has received $1.

Transgenomic Provides Update On Its Planned Merger And Reports Change In Listing Status

Transgenomic, Inc. (TBIO) (OTCQB: TBIO) today reported that trading in its shares will begin on the OTCQB exchange under the ticker "TBIO" effective at the open of business on February 22, 2017.

These 5 Stocks Under $10 Could Explode Higher Soon

These 5 Stocks Under $10 Could Explode Higher Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR As Its Mutation Enrichment Platform

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR As Its Mutation Enrichment Platform

Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected Transgenomic's ICE COLD-PCR (ICP) technology as its mutation...

Transgenomic And Precipio Diagnostics Announce Planned Merger

Transgenomic And Precipio Diagnostics Announce Planned Merger

Transgenomic, Inc. (NASDAQ:TBIO), and privately-held Precipio Diagnostics, LLC today announced entry into a merger agreement, pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic, and...

Transgenomic Adds New Distributors In China And India For Its ICEme Kits That Enable Liquid Biopsy Cancer Testing On Existing Platforms

Transgenomic Adds New Distributors In China And India For Its ICEme Kits That Enable Liquid Biopsy Cancer Testing On Existing Platforms

Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced that it has signed agreements with two additional distributors in China and India for its ICEme™ Mutation Enrichment Kits for cancer genomic testing.

Transgenomic And Ventana Medical Systems Complete Data Sharing Agreement

Transgenomic And Ventana Medical Systems Complete Data Sharing Agreement

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO), today announced that it has signed a data sharing agreement with Ventana Medical Systems, Inc.

Transgenomic Reports Second Quarter 2016 Financial Results

Transgenomic Reports Second Quarter 2016 Financial Results

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) today reported financial results for the second quarter ended June 30, 2016, and provided a business update.

Transgenomic To Hold Second Quarter 2016 Results Conference Call On August 12, 2016 At 5:00 PM EDT

Transgenomic To Hold Second Quarter 2016 Results Conference Call On August 12, 2016 At 5:00 PM EDT

Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its Second Quarter 2016 Financial Results and Business Update Conference Call on August 12, 2016 at 5:00 PM EDT.

VWR To Distribute Transgenomic's ICEme Kits That Enable Liquid Biopsy-Based Cancer Research On Existing Platforms

VWR To Distribute Transgenomic's ICEme Kits That Enable Liquid Biopsy-Based Cancer Research On Existing Platforms

Transgenomic, Inc. (NASDAQ: TBIO) today announced it has signed a non-exclusive agreement with VWR (NASDAQ: VWR) for distribution of its ICEme™ Mutation Enrichment Kits to researchers and laboratories in North America.

Transgenomic Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer

Transgenomic Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) today announced the launch of its new CLIA assays that detect the presence of the EGFR C797S mutation, a novel mechanism of acquired resistance to third-generation tyrosine kinase...

Transgenomic Licenses Commercial Rights To Its Long QT Syndrome DNA Testing Portfolio To LabCorp

Transgenomic Licenses Commercial Rights To Its Long QT Syndrome DNA Testing Portfolio To LabCorp

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) , today announced that it has signed a commercial license agreement with Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) for TBIO's portfolio of...

Transgenomic Accelerates Commercialization Of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold

Transgenomic Accelerates Commercialization Of ICE COLD-PCR (ICP) Amid Plans To Expand Cancer Product Line Ten-Fold

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) , today announced plans to expand its ICE COLD-PCR (ICP)-powered cancer assays ten-fold over the next 18 months, targeting a portfolio of more than 200 exons/mutations expected to...

Transgenomic Releases New Data At ASCO 2016 Confirming Concordance Of ICE COLD-PCR (ICP) Liquid And Tissue Biopsies

Transgenomic Releases New Data At ASCO 2016 Confirming Concordance Of ICE COLD-PCR (ICP) Liquid And Tissue Biopsies

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO), today announced that it is unveiling new data at the American Society for Clinical Oncology (ASCO) 2016 Annual Meeting further confirming the utility, speed and efficiency of its...

Trade These 5 Stocks Now to Catch Big Breakout Gains

Trade These 5 Stocks Now to Catch Big Breakout Gains

These five stocks are setting up to break about and trade higher from current levels.

Transgenomic Reports First Quarter 2016 Financial Results

Transgenomic Reports First Quarter 2016 Financial Results

Transgenomic, Inc. (NASDAQ: TBIO) today reported financial results for the first quarter ended March 31, 2016, and provided a business update.

Transgenomic To Hold First Quarter 2016 Results Conference Call On May 24, 2016 At 9:00 AM EDT

Transgenomic To Hold First Quarter 2016 Results Conference Call On May 24, 2016 At 9:00 AM EDT

Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its First Quarter 2016 Financial Results and Business Update Conference Call on May 24, 2016 at 9:00 AM EDT.

Transgenomic Study Data Shows 100% Concordance Between ICE COLD-PCR™ (ICP) Liquid Biopsies And Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods

Transgenomic Study Data Shows 100% Concordance Between ICE COLD-PCR™ (ICP) Liquid Biopsies And Conventional Tissue Biopsy Results; ICP Also Identifies More Tumor Mutations Than Conventional Methods

Transgenomic, Inc. (NASDAQ:TBIO) , today announced new concordance study data confirming the superior performance of its ICE COLD-PCR ™ (ICP) enrichment technology over standard biopsied tissue PCR results for...

Transgenomic Unveils The First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel At AACR 2016 Annual Meeting

Transgenomic Unveils The First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel At AACR 2016 Annual Meeting

Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) , today announced that it is unveiling its new Breast Cancer Analysis Panel this week at the 2016 American Association for Cancer Research (AACR) Annual Meeting.

Transgenomic Reports Full Year 2015 Financial Results

Transgenomic Reports Full Year 2015 Financial Results

Transgenomic, Inc. (NASDAQ: TBIO) today is reporting financial results for the year ended December 31, 2015, and providing a business update.

Transgenomic To Hold Full Year Financial Results Conference Call On April 14, 2016 At 5:00 PM ET

Transgenomic To Hold Full Year Financial Results Conference Call On April 14, 2016 At 5:00 PM ET

Transgenomic, Inc. (NASDAQ: TBIO), today announced that the company will hold its Fourth Quarter and Year-End 2015 Financial Results and Business Update Conference Call on Thursday, April 14, 2016 at 5:00 PM ET.

Transgenomic To Present Data Confirming Utility Of ICE COLD-PCR Liquid Biopsy Technology At American Association For Cancer Research 2016 Annual Meeting

Transgenomic To Present Data Confirming Utility Of ICE COLD-PCR Liquid Biopsy Technology At American Association For Cancer Research 2016 Annual Meeting

Transgenomic, Inc. (NASDAQ: TBIO), today announced that company scientists will present new data at the upcoming American Association for Cancer Research (AACR) 2016 Annual Meeting highlighting the utility of its ICE...

Transgenomic Launches First Commercially Available Assay For Ultra Low Level Detection Of EGFR C797S Mutations That Predict Resistance To Third Generation Kinase Therapies For Lung Cancer

Transgenomic Launches First Commercially Available Assay For Ultra Low Level Detection Of EGFR C797S Mutations That Predict Resistance To Third Generation Kinase Therapies For Lung Cancer

Transgenomic, Inc. (NASDAQ: TBIO) today announced the launch of its EGFR C797S Mutation Detection Assay based on the company's ICE COLD-PCR ™ (ICP) technology.

Transgenomic Launches New MX-ICP Liquid Biopsy Tests For Comprehensive Detection Of Colorectal And Melanoma Tumor Mutations

Transgenomic Launches New MX-ICP Liquid Biopsy Tests For Comprehensive Detection Of Colorectal And Melanoma Tumor Mutations

Transgenomic, Inc. (NASDAQ:TBIO) today announced the launch of its MX-ICP CRC Analysis and MX-ICP Melanoma Analysis, two new liquid biopsy cancer panels based on the company's Multiplexed ICE COLD-PCR ™ (MX-ICP)...

Transgenomic Highlights Unique Advantages Of Multiplexed ICE COLD-PCR™ At Personalized Medicine World Conference

Transgenomic Highlights Unique Advantages Of Multiplexed ICE COLD-PCR™ At Personalized Medicine World Conference

Transgenomic, Inc. (NASDAQ:TBIO) today announced that Ben Legendre, Jr.

Transgenomic Launches New MX-ICP Panels For Liquid Biopsy Detection Of RAS And PIK3CA Tumor Mutations

Transgenomic Launches New MX-ICP Panels For Liquid Biopsy Detection Of RAS And PIK3CA Tumor Mutations

Transgenomic, Inc. (NASDAQ: TBIO) today announced the launch of the MX-ICP RAS Analysis and the MX-ICP PIK3CA Analysis, two new cancer panels based on the company's Multiplexed ICE-COLD PCR ™ (MX-ICP) technology.